EyePoint Pharmaceuticals Inc (EYPT)

[BioSpecialist]

PSDV..A great Opportunity ..Newbies Read !!

MarketCap only 94 Mio$ is way too Cheap

Shares Out 18,2 M ..Listed in USA,Australia and Germany

Rodman Slide Presentation Sep 2009
http://www.wsw.com/webcast/rrshq15/psdv/

Pipeline
http://www.psivida.com/products.html

Major Shareholder
http://phx.corporate-ir.net/phoenix.zhtml?c=168274&p=irol-ownershipSummary

pSivida is a leader in the development of miniaturized, injectable, drug delivery systems. We develop products to treat serious or life threatening diseases alone or in partnership with other companies. We have developed devices that are so small they are FDA approved to be administered into the eye and once administered they release their drug for months and years.

pSivida’s lead development product, Iluvien™, delivers fluocinolone acetonide (FA). Formerly known as Medidur™ FA for DME, Iluvien is in fully recruited Phase III clinical trials for the treatment of diabetic macular edema (DME), one of the leading causes of blindness in the developed world. Iluvien is designed to provide sustained release of drug for up to three years after a single injection. It is also in Phase II clinical trials for the treatment of dry age-related macular degeneration (dry-AMD) and wet age- related macular degeneration (wet-AMD). These studies are being conducted and fully funded by our licensee, Alimera Sciences.

pSivida’s two FDA approved sustained release products to treat chronic back of the eye diseases are Retisert® for the treatment of posterior uveitis and Vitrasert® for the treatment of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. Vitrasert and Retisert provide sustained release for six to nine months and two and a half years, respectively.

pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. to develop additional ophthalmic products.

pSivida is developing a series of additional miniaturized, bioerodible technologies designed to provide long term (months and years) release to virtually any site in the body. One of these technologies is BioSilicon™, a bioerodible form of silicon. The most advanced BioSilicon product candidate, BrachySil™, is in a dose ranging clinical trial to treat pancreatic cancer. BrachySil is designed to deliver a therapeutic P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors to minimize side effects and maximize efficacy. pSivida has completed an initial safety study of BrachySil for the treatment of pancreatic cancer and a dose ranging study has completed enrollment.

pSivida’s intellectual property portfolio consists of over 45 patent families, over 100 granted patents, including patents accepted for issuance, and over 200 patent applications. pSivida conducts its operations from Boston in the United States and Malvern in the United Kingdom.